GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lirum Therapeutics Inc (NAS:LRTX) » Definitions » 3-Year EBITDA Growth Rate

Lirum Therapeutics (Lirum Therapeutics) 3-Year EBITDA Growth Rate : 0.00% (As of Dec. 2023)


View and export this data going back to 2024. Start your Free Trial

What is Lirum Therapeutics 3-Year EBITDA Growth Rate?

Lirum Therapeutics's EBITDA per Share for the three months ended in Dec. 2023 was $-0.03.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.


Competitive Comparison of Lirum Therapeutics's 3-Year EBITDA Growth Rate

For the Biotechnology subindustry, Lirum Therapeutics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lirum Therapeutics's 3-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lirum Therapeutics's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Lirum Therapeutics's 3-Year EBITDA Growth Rate falls into.



Lirum Therapeutics 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.


Lirum Therapeutics  (NAS:LRTX) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.


Lirum Therapeutics 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Lirum Therapeutics's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Lirum Therapeutics (Lirum Therapeutics) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
590 Madison Avenue, 21st Floor, New York, NY, USA, 10022
Lirum Therapeutics Inc is clinical-stage biopharmaceutical company focused on the treatment of debilitating diseases through the acquisition, development, and commercialization of novel drug candidates with compelling mechanisms of action, regulatory pathways, and commercial opportunities. Its product candidate, LX-101, formerly 765IGF-MTX, is a novel, clinical-stage, "next generation," precision-engineered targeted therapy directed to the IGF-1R.

Lirum Therapeutics (Lirum Therapeutics) Headlines

No Headlines